Almac launches Biomarkers for Biopharma
Firm says biomarkers can add value to compounds in development
Almac aims to enable biopharma firms to understand their drugs better and improve their drug’s success rate and value with the launch of Biomarkers for Biopharma solutions.
The Craigavon, Ireland-based firm says biomarkers can add substantial value to a compound in development and the ability to identify those patients most likely to respond to a therapy greatly increases the chances of success and the licensing potential of the drug.
Almac’s Biomarkers for biopharma solutions include pharmacodynamic solutions, patient selection markers, assay development and bioinformatics/biostatistics consultancy.
Professor Paul Harkin, president and md of Almac's Diagnostics division, said: ‘With Biomarkers for biopharma we have combined a range of key solutions which are ideally suited to growing biopharma companies. For these companies, it is of critical importance that they maximise the potential success of the drugs in their pipeline and the incorporation of a biomarker strategy enables them to do this.’
